36
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.

          Related collections

          Author and article information

          Journal
          Lancet Oncol
          The Lancet. Oncology
          Elsevier BV
          1474-5488
          1470-2045
          Dec 2013
          : 14
          : 13
          Affiliations
          [1 ] National Cancer Center Hospital, Tokyo, Japan. Electronic address: yayamada@ncc.go.jp.
          Article
          S1470-2045(13)70490-X
          10.1016/S1470-2045(13)70490-X
          24225157
          08de67ee-a6b7-481f-a05c-a02dd5e1a6bc
          Copyright © 2013 Elsevier Ltd. All rights reserved.
          History

          Comments

          Comment on this article